/
CTXR
$0.58+$0.04 (+7.15%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$14.8M
27M shares
52-week range
$0.48 – $2.48
5% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
37.52%
Hard to borrow
Price (6 mo)
Loading chart…
Change$-64.42
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $1.8K | $893 | $152.4K | $164.9K | $179.7K | $194.3K | $209.6K | $214.3K |
| Gross profit | −$1.8K | −$893 | −$152.4K | −$164.9K | −$179.7K | −$194.3K | −$209.6K | −$214.3K |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $6.6M | $8.6M | $8.8M | $12.2M | $17.7M | $14.8M | $11.9M | $9.2M |
| Operating income | −$13.8M | −$15.6M | −$17.7M | −$23.5M | −$33.3M | −$36.7M | −$42.0M | −$38.5M |
| EBITDA | −$13.8M | −$15.5M | −$17.4M | −$22.9M | −$32.9M | −$31.8M | −$38.6M | −$38.2M |
| Net income | −$12.5M | −$15.6M | −$17.5M | −$23.1M | −$33.6M | −$32.5M | −$39.1M | −$37.4M |
| Net margin | — | — | — | — | — | — | — | — |
| EPS (diluted) | -1.17 | -0.77 | -0.45 | -5.64 | -5.76 | -5.57 | -5.97 | -3.38 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $21M | $-1.87 | $-1.87–$-1.87 | 1 |
| 2027 | $53M | $-0.81 | $-0.81–$-0.81 | 1 |
| 2028 | $105M | $0.11 | $0.11–$0.11 | 1 |
| 2029 | $142M | $0.60 | $0.60–$0.60 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.93
Price
$0.58
Implied upside
+60%
Peer comparison
Citius Pharmaceuticals Inc. Common
Citius Pharmaceuticals Inc is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, with a focus on oncology, anti-infectives in adjunct cancer care and distinct prescription products. It aims to provide therapeutic products that address unmet medical needs yet have a lower development risk than is usually associated with new chemical entities. The company's flagship product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein. It operates through a single operating and reportable segment which is focused on developing and commercializing pioneering targeted oncology therapies.
www.citiuspharma.com- Employees
- 23
- IPO / List date
- Oct 18, 2011
- HQ
- CRANFORD, NJ
Held by traders on TradeandTell
No one on the platform currently holds CTXR.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in CTXR as of their last filing.
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2024-11-26 | 1-for-25reverse |
| 2017-06-09 | 1-for-15reverse |
Recent trades on TradeandTell
No one on the platform has traded CTXR yet.
